Coherus Biosciences, INC 8-K filings

Coherus BioSciences has appointed Rita A. Karachun, a former SVP and Global Controller at Merck, to its Board of Directors, effective May 31, 2024.

Coherus BioSciences held its 2024 Annual Meeting of Stockholders, electing three Class I directors, ratifying its accounting firm, and approving executive compensation and an equity incentive plan amendment.

Coherus BioSciences has entered into a revenue participation right purchase and sale agreement and a senior secured term loan facility, securing new financing.

Coherus BioSciences announced positive first quarter 2024 financial results, highlighted by a significant increase in revenue and the successful launch of LOQTORZI.

Coherus BioSciences has entered into a new $38.7 million term loan facility and sold revenue participation rights for $37.5 million to refinance existing debt and bolster its financial position.

Coherus BioSciences divested its ophthalmology franchise, reduced its workforce by 30%, and reported full year 2023 financial results, highlighting a strategic shift towards oncology.

Coherus BioSciences has completed the divestiture of its ophthalmology franchise, including CIMERLI, to Sandoz for $170 million in upfront cash, plus $17.8 million for inventory and prepaid assets.

Coherus BioSciences has expanded its board of directors by appointing Georgia Erbez as a Class III director, effective February 20, 2024.

Coherus BioSciences has amended its loan agreement with Pharmakon Advisors, LP, allowing for a $175 million debt reduction following the sale of its ophthalmology business to Sandoz.

Coherus BioSciences has agreed to sell its ophthalmology business, including CIMERLI, to Sandoz for $170 million in cash, plus inventory value and adjustments.